scholarly journals Clinical practice and short-term efficacy of 2.45-GHz microwave endometrial ablation to treat menorrhagia

2015 ◽  
Vol 4 (3) ◽  
pp. 76-80 ◽  
Author(s):  
Naoki Matsumoto ◽  
Nobuyuki Ikeda ◽  
Toshifumi Takenaka ◽  
Satoshi Yazaki ◽  
Yuichi Sato
Keyword(s):  
Clinical Practice ◽  
Endometrial Ablation ◽  
Short Term ◽  
Microwave Endometrial Ablation ◽  
Term Efficacy

scholarly journals Testing the Short-Term Efficacy of a Lipid-Lowering Nutraceutical in the Setting of Clinical Practice: A Multicenter Study

2015 ◽  
Vol 18 (11) ◽  
pp. 1270-1273 ◽  
Author(s):  
Arrigo F.G. Cicero ◽  
Giuseppe Derosa ◽  
Livia Pisciotta ◽  
Carlo Barbagallo ◽  
Keyword(s):  
Clinical Practice ◽  
Multicenter Study ◽  
Lipid Lowering ◽  
Short Term ◽  
Term Efficacy

Tildrakizumab: short‐term efficacy and safety in real clinical practice

2021 ◽  
Author(s):  
Manuel Galán‐Gutierrez ◽  
Lourdes Rodriguez‐Fernandez Freire ◽  
Ricardo Ruiz‐Villaverde
Keyword(s):  
Clinical Practice ◽  
Efficacy And Safety ◽  
Short Term ◽  
Term Efficacy ◽  
Real Clinical Practice

scholarly journals Short-term Efficacy Study of Lower Tibial Combination Separation in the Treatment of TightRopeight

2017 ◽  
Vol 1 (3) ◽  
Author(s):  
Xue Yong
Keyword(s):  
Clinical Practice ◽  
Blood Loss ◽  
Inflammatory Response ◽  
Efficacy Study ◽  
Intraoperative Blood Loss ◽  
Short Term ◽  
Aofas Score ◽  
Term Efficacy

Objective: To explore the recent efficacy of Lower TibialCombination Separation in the treatment of TightRopeight.Methods: 60 patients were selected as object with lower tibialcombination separation treated in our hospital from May 2013 toMay 2016. All patients were treated with TightRopeight, and theshort-term efficacy has been analyzed. Results: Apart from the 5cases of inflammatory response, other patients were healed wellwith lower intraoperative blood loss and no postoperative re-fracture. The excellent rate of AOFAS score was 96.67%.Conclusion: Applying TightRopeight in the treatment of patientswith lower tibial combination separation can not only achieve goodshort-term efficacy, but also have lower recurrence and highersafety rate a, which is worthy of further promotion and applicationin clinical practice.

Short‐term efficacy of a gel containing propolis extract, nanovitamin C and nanovitamin E on peri‐implant mucositis: A double‐blind, randomized, clinical trial

2021 ◽  
Author(s):  
José González‐Serrano ◽  
Rosa María López‐Pintor ◽  
Julia Serrano ◽  
Jesús Torres ◽  
Gonzalo Hernández ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Short Term ◽  
Double Blind ◽  
Propolis Extract ◽  
Term Efficacy

scholarly journals Evaluation of the short-term efficacy of local analgesic (lidocaine) and opioid analgesic (sufentanil) on patients with centrally mediated abdominal pain syndrome: a randomized controlled trial

2021 ◽  
Vol 14 ◽  
pp. 175628482110217
Author(s):  
Hang Yang ◽  
Honglin Chen ◽  
Bing Hu
Keyword(s):  
Randomized Controlled Trial ◽  
Abdominal Pain ◽  
Rating Scales ◽  
Rating Scale ◽  
Controlled Trial ◽  
Opioid Analgesic ◽  
Pain Syndrome ◽  
Short Term ◽  
Randomized Controlled ◽  
Term Efficacy

Background: Centrally mediated abdominal pain syndrome (CAPS) is characterized by continuous or frequently recurring abdominal pain and can result in functional loss across several life domains. The efficacy of the present management methods has not been established yet. We performed a prospective randomized controlled trial to explore the short-term efficacy of local analgesic (lidocaine) and opioid analgesic (sufentanil) in patients with CAPS. Methods: We consecutively enrolled 130 patients who met the Rome IV CAPS criteria and divided them into the sufentanil + lidocaine (S + L) group and sufentanil (S) group. Patients completed the pain rating scales, including the numeric rating scale (NRS) and verbal rating scale (VRS), 60 min before colonoscopy. All the patients were initially administered sufentanil. In the S + L group, we sprayed a 5 ml solution of lidocaine on the surface of ascending, transverse, descending, and sigmoid colon during colonoscope withdrawal, while 5 ml saline was sprayed in the S group. Follow up was performed 1 day, 3 days, 1 week, 2 weeks, 1 month, and 3 months after colonoscopy, to complete the pain scaling. Results: A comparison of the NRS and VRS showed that there were no significant differences between the S + L and S groups and within each group ( p > 0.05). Conclusions: Local analgesic lidocaine and opioid analgesic sufentanil showed negative efficacy during short-term observation. The opioid receptor blocker sufentanil did not worsen symptoms in patients with CAPS after colonoscopy under general anesthesia in the short term. [chictr.org.cn, Chinese Clinical Trial Identifier, ChiCTR-IOR-16008187]

scholarly journals Predictors for clinical effectiveness of baricitinib in rheumatoid arthritis patients in routine clinical practice: data from a Japanese multicenter registry

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Nobunori Takahashi ◽  
Shuji Asai ◽  
Tomonori Kobayakawa ◽  
Atsushi Kaneko ◽  
Tatsuo Watanabe ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Clinical Practice ◽  
Disease Activity ◽  
Retention Rate ◽  
Oral Prednisone ◽  
Multivariate Logistic Regression Analysis ◽  
Jak Inhibitors ◽  
Short Term ◽  
History Of ◽  
Multicenter Registry

AbstractThis study aimed to evaluate the short-term effectiveness and safety profiles of baricitinib and explore factors associated with improved short-term effectiveness in patients with rheumatoid arthritis (RA) in clinical settings. A total of 113 consecutive RA patients who had been treated with baricitinib were registered in a Japanese multicenter registry and followed for at least 24 weeks. Mean age was 66.1 years, mean RA disease duration was 14.0 years, 71.1% had a history of use of biologics or JAK inhibitors (targeted DMARDs), and 48.3% and 40.0% were receiving concomitant methotrexate and oral prednisone, respectively. Mean DAS28-CRP significantly decreased from 3.55 at baseline to 2.32 at 24 weeks. At 24 weeks, 68.2% and 64.1% of patients achieved low disease activity (LDA) and moderate or good response, respectively. Multivariate logistic regression analysis revealed that no previous targeted DMARD use and lower DAS28-CRP score at baseline were independently associated with achievement of LDA at 24 weeks. While the effectiveness of baricitinib was similar regardless of whether patients had a history of only one or multiple targeted DMARDs use, patients with previous use of non-TNF inhibitors or JAK inhibitors showed lower rates of improvement in DAS28-CRP. The overall retention rate for baricitinib was 86.5% at 24 weeks, as estimated by Kaplan–Meier analysis. The discontinuation rate due to adverse events was 6.5% at 24 weeks. Baricitinib significantly improved RA disease activity in clinical practice. Baricitinib was significantly more effective when used as a first-line targeted DMARDs.

Sign in / Sign up

Export Citation Format

Share Document